Melanoma

Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy
Merck's Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients
French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial
Merck's Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients
French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial
Merck's Keytruda Wins Eighth FDA Approval Of 2021, This Time For Adjuvant, Pediatric Melanoma Settings
New Data Reaffirms Merck's Keytruda In Extending Survival In Melanoma Patients

Melanoma Recent News

OncoSec Stock Jumps On Anti-Cancer Gene Therapy Trial Collaboration With Merck In Melanoma
BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial
BriaCell Extends Personalized Breast Cancer Immunotherapy To Prostate & Lung Cancer And Melanoma
Sorrento, Mayo Clinic Ink Research Pact For Ipilimumab-Delivering Sofusa In Melanoma Patients
Iovance's Lifileucel Shows Meaningful Increase in Response Time with Primary Anti-PD-1 Resistance in Melanoma Trial
Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced updated clinical data for lifileucel from Cohort 2 of C-144-01 clinical study in patients with advanced melanoma. Data were presented at the ASCO 2021 Annual Meeting.
Iovance Shares Jump After Lifileucel Achieves 86% Response Rate In Melanoma Trial
Bristol Myers' Relatlimab/Opdivo Combo Therapy Tops Opdivo Alone in Untreated Melanoma Patients
Idera Will Not Continue Tilsotolimod/Ipilimumab Combo Melanoma Trial Into OS Primary Endpoint
Alkermes Launches Mid-Stage Melanoma Study Of Nemvaleukin As Monotherapy
Why Idera Pharmaceuticals Shares Dropped 62% Lower Today
Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet the primary endpoint in a Phase 3 trial for anti-PD-1 refractory advanced melanoma.
Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development
Anlayst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside
Sensus Healthcare CEO On Republican Government: 'Our Product Can Survive'
Sensus Healthcare CEO On IPO, Finances And Stock Performance: 'We Are Very Comfortable'
Sensus Healthcare CEO Shares A Look Into Skin Cancer Treatment
The Street Is Seeing Higher Probability Of Success For Incyte's Melanoma Treatment
Presidential Merck: 'Jimmy Carter' Oncology Drug Expected To Dominate, Hep C Drug Approved Across EU
Jimmy Carter Boosts Social Media Buzz For Merck's Blockbuster Drug
Why Shares Of Array Biopharma Are Surging More Than 35%